NO20080523L - Heteroarylsubstituerte amider omfattende en mettet bindingsgruppe og deres anvendelse som farmasoytiske midler - Google Patents

Heteroarylsubstituerte amider omfattende en mettet bindingsgruppe og deres anvendelse som farmasoytiske midler

Info

Publication number
NO20080523L
NO20080523L NO20080523A NO20080523A NO20080523L NO 20080523 L NO20080523 L NO 20080523L NO 20080523 A NO20080523 A NO 20080523A NO 20080523 A NO20080523 A NO 20080523A NO 20080523 L NO20080523 L NO 20080523L
Authority
NO
Norway
Prior art keywords
formula
compounds
synthase
expression
endothelial
Prior art date
Application number
NO20080523A
Other languages
English (en)
Norwegian (no)
Inventor
Hartmut Strobel
Paulus Wohlfart
Gerhard Zoller
David William Will
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20080523L publication Critical patent/NO20080523L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20080523A 2005-06-28 2008-01-28 Heteroarylsubstituerte amider omfattende en mettet bindingsgruppe og deres anvendelse som farmasoytiske midler NO20080523L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05013870A EP1741709A1 (en) 2005-06-28 2005-06-28 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
PCT/EP2006/005706 WO2007000246A1 (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
NO20080523L true NO20080523L (no) 2008-01-28

Family

ID=35478793

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080523A NO20080523L (no) 2005-06-28 2008-01-28 Heteroarylsubstituerte amider omfattende en mettet bindingsgruppe og deres anvendelse som farmasoytiske midler

Country Status (32)

Country Link
US (1) US8518976B2 (sr)
EP (2) EP1741709A1 (sr)
JP (1) JP5149794B2 (sr)
KR (1) KR20080027801A (sr)
CN (1) CN101208328B (sr)
AR (1) AR054800A1 (sr)
AT (1) ATE539072T1 (sr)
AU (1) AU2006264049B2 (sr)
BR (1) BRPI0613717A2 (sr)
CA (1) CA2611953A1 (sr)
CY (1) CY1112869T1 (sr)
DK (1) DK1899321T3 (sr)
DO (1) DOP2006000146A (sr)
ES (1) ES2378894T3 (sr)
GT (1) GT200600274A (sr)
HR (1) HRP20120167T1 (sr)
IL (1) IL188382A0 (sr)
MA (1) MA29552B1 (sr)
MX (1) MX2008000044A (sr)
NO (1) NO20080523L (sr)
NZ (1) NZ565041A (sr)
PA (1) PA8683901A1 (sr)
PE (1) PE20070102A1 (sr)
PL (1) PL1899321T3 (sr)
PT (1) PT1899321E (sr)
RS (1) RS52266B (sr)
RU (1) RU2412181C2 (sr)
SI (1) SI1899321T1 (sr)
TW (1) TWI378095B (sr)
UY (1) UY29640A1 (sr)
WO (1) WO2007000246A1 (sr)
ZA (1) ZA200710002B (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
US8815772B2 (en) 2012-06-29 2014-08-26 E I Du Pont De Nemours And Company Fungicidal heterocyclic carboxamides
CN110128406B (zh) 2013-04-12 2021-08-27 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
EP4359387A1 (en) * 2021-06-25 2024-05-01 Jazz Pharmaceuticals Ireland Limited Sulfonamide orexin receptor agonists and uses thereof
CN116987511A (zh) * 2022-04-26 2023-11-03 丰益表面活性材料（连云港）有限公司 一种n-酰基氨基酸表面活性剂制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4429656Y1 (sr) 1967-03-16 1969-12-08
GB1188416A (en) * 1968-04-01 1970-04-15 Ici Ltd Heterocyclic Amines
GB1231829A (sr) * 1968-09-19 1971-05-12
GB1341375A (en) * 1969-11-19 1973-12-19 Smith Kline French Lab Aminoalkylimidazoles and process for their production
FR2510997A1 (fr) 1981-08-10 1983-02-11 Sanofi Sa Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant
CA1218655A (en) 1983-01-28 1987-03-03 Kathleen Biziere Process for the preparation of pyridazine derivatives having a psychotropic action
DE3685840D1 (de) 1985-04-30 1992-08-06 Dresden Arzneimittel 3-cyan-pyridine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
US4710502A (en) 1985-11-04 1987-12-01 American Cyanamid Company 3-heteroarylalkyl-4-quinazolinones
US4701502A (en) * 1985-12-13 1987-10-20 E. I. Du Pont De Nemours And Company Chip resistant primer composition V'
NL8800998A (nl) * 1988-04-18 1989-11-16 Cedona Pharm Bv Werkwijze voor het bereiden van een al of niet gesubstitueerd 4(5)-(omega-aminoalkyl) imidazool.
TW224974B (sr) * 1991-07-02 1994-06-11 Hoffmann La Roche
GB9127304D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5684008A (en) * 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
WO1996018616A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
DE69717148T2 (de) 1996-12-10 2003-10-02 Abbott Laboratories, Abbott Park 3-pyridylenantiomere und ihre verwendung als analgetika
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO2000003746A2 (en) 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
SE9803518D0 (sv) * 1998-10-15 1998-10-15 Astra Pharma Prod Novel compounds
AU3511500A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
JP2002255971A (ja) * 2000-03-31 2002-09-11 Takeda Chem Ind Ltd 縮合複素環誘導体、その製造法および用途
CA2400858A1 (en) 2000-03-31 2001-10-11 Shokyo Miki Fused heterocyclic derivatives, their production and use
CA2415899A1 (en) * 2000-07-18 2003-01-13 Chikashi Saitoh Medicine comprising dicyanopyridine derivative
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
MY136316A (en) 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
BR0209774A (pt) * 2001-05-29 2004-06-01 Schering Ag Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
JPWO2003022821A1 (ja) * 2001-09-06 2004-12-24 大正製薬株式会社 ２０−ｈｅｔｅ産生酵素阻害作用を有するヘテロ環誘導体
ATE407678T1 (de) 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
DE10201240A1 (de) 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
FR2837201A1 (fr) 2002-03-18 2003-09-19 Servier Lab Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1492784A4 (en) * 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
WO2003094845A2 (en) * 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388342A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
CA2529611C (en) * 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
EP1587510A4 (en) * 2003-01-31 2007-08-08 Univ Hong Kong METHOD OF TREATING ISCHEMIC BUST WITH MELATONIN
JP2004262890A (ja) * 2003-03-04 2004-09-24 Taisho Pharmaceut Co Ltd ２０−ｈｅｔｅ産生阻害作用を有するアゾール誘導体
JP2004269469A (ja) * 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
EP1471066A1 (en) 2003-04-24 2004-10-27 Aventis Pharma Deutschland GmbH Triaza- and tetraaza-anthracenedione derivates, their preparation and their use as pharmaceuticals
US7538233B2 (en) * 2003-09-05 2009-05-26 Aventis Pharmaceuticals Inc. Coumarins as iNOS inhibitors
WO2005048926A2 (en) * 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
AU2005205201B2 (en) * 2004-01-12 2011-05-12 Merck Serono Sa Thiazole derivatives and use thereof
GB0402809D0 (en) 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1899321A1 (en) 2008-03-19
SI1899321T1 (sl) 2012-04-30
BRPI0613717A2 (pt) 2011-02-08
KR20080027801A (ko) 2008-03-28
JP2008543958A (ja) 2008-12-04
CN101208328B (zh) 2012-02-29
RU2412181C2 (ru) 2011-02-20
MX2008000044A (es) 2008-03-19
ZA200710002B (en) 2008-11-26
GT200600274A (es) 2007-02-05
ES2378894T3 (es) 2012-04-18
PT1899321E (pt) 2012-03-19
CY1112869T1 (el) 2016-04-13
JP5149794B2 (ja) 2013-02-20
RU2008102966A (ru) 2009-08-10
AU2006264049B2 (en) 2012-04-12
US20080171739A1 (en) 2008-07-17
PL1899321T3 (pl) 2012-05-31
UY29640A1 (es) 2007-01-31
CN101208328A (zh) 2008-06-25
PE20070102A1 (es) 2007-03-02
AR054800A1 (es) 2007-07-18
MA29552B1 (fr) 2008-06-02
DOP2006000146A (es) 2006-12-31
TWI378095B (en) 2012-12-01
CA2611953A1 (en) 2007-01-04
AU2006264049A1 (en) 2007-01-04
HK1122551A1 (en) 2009-05-22
WO2007000246A1 (en) 2007-01-04
IL188382A0 (en) 2008-04-13
DK1899321T3 (da) 2012-04-16
ATE539072T1 (de) 2012-01-15
PA8683901A1 (es) 2007-01-17
EP1899321B1 (en) 2011-12-28
HRP20120167T1 (hr) 2012-03-31
US8518976B2 (en) 2013-08-27
EP1741709A1 (en) 2007-01-10
TW200738673A (en) 2007-10-16
NZ565041A (en) 2011-03-31
RS52266B (sr) 2012-10-31

Similar Documents

Publication Publication Date Title
WO2008074413A3 (en) Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial no synthase
NO20051110L (no) Acylerte arylsykloalkylaminer og deres anvedelse som farmasoytiske midler
TW200800941A (en) Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
NO20080523L (no) Heteroarylsubstituerte amider omfattende en mettet bindingsgruppe og deres anvendelse som farmasoytiske midler
WO2008104278A8 (en) Imidazo[1,2-a] pyridines and their use as pharmaceuticals
BR0313294A (pt) Compostos heteroaromáticos substituìdos com acilamino e seu uso como substâncias farmacêuticas
BR0313240A (pt) Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos
NO20074647L (no) 3,4 dihydro-1H-isoquinolin-2-karboksylsyre-5-ammopyridin-2-yl estere
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20071245L (no) Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer.
NO20084845L (no) 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
NO20060168L (no) Pyridinylkarbamater som hormonsensitive lipaseinhibitorer
NO20070432L (no) Pyrimidinureaderivater som kinaseinhibitorer
NO20070445L (no) Pyrimidinderivater.
NO20082709L (no) Kjemiske forbindelser
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
WO2005077950A3 (en) Medicaments with hm74a receptor activity
Abbhi et al. Rho-kinase (ROCK) inhibitors-a neuroprotective therapeutic paradigm with a focus on ocular utility
NO20071005L (no) Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer
MX2009011753A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
Kolluru et al. Rho-kinase as a therapeutic target in vascular diseases: striking nitric oxide signaling
DE602006006985D1 (de) Pyridinderivate als pkc-theta-hemmer
MXPA05011267A (es) Derivados de la triaza-y tetraaza-antracenodiona, su preparacion y su uso como productos farmaceuticos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application